Eosinophilic Esophagitis- Pipeline Insight, 2018

SKU ID : DEL-

Publishing Date : 07-Mar-2018

No. of pages : 63

PRICE
1250
4000


  • "Eosinophilic Esophagitis- Pipeline Insight, 2018" report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across Eosinophilic Esophagitis. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 10+ products along with 10+ companies involved.
    Products covered by Phase
    • Phase III and Phase II
    • Pre-clinical
    • Inactive (Dormant and Discontinued)
    Overview of pipeline development activities for Eosinophilic Esophagitis
    Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
    Therapeutic segmentation of products for Eosinophilic Esophagitis
    The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
    Scope of the report
    • Provides an overview of therapeutic pipeline activity for Eosinophilic Esophagitis across the complete product development cycle including all clinical and non-clinical stages
    • It comprises of detailed profiles of Eosinophilic Esophagitis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
    • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    • Coverage of dormant and discontinued pipeline projects across Eosinophilic Esophagitis

    Reasons to Buy
    • Establish a comprehensive understanding of the current pipeline scenario across Eosinophilic Esophagitis to formulate effective R&D strategies
    • Assess challenges and opportunities that influence Eosinophilic Esophagitis R&D
    • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
    • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Eosinophilic Esophagitis to enhance and expand business potential and scope
    • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

    Detailed TOC of Eosinophilic Esophagitis- Pipeline Insight, 2018

    Executive Summary
    Overview
    Eosinophilic Esophagitis
    History
    Symptoms
    Diagnosis
    Pathophysiology
    Genetics of Eosinophilic Esophagitis
    Treatment
    Emerging therapies for Eosinophilic Esophagitis
    Pipeline Therapeutics
    Comparative Analysis
    Late Stage Products (Phase III)
    Comparative Analysis
    SHP621: Shire
    Product Description
    Research and Development
    Product Development Activities
    (The list continues)
    Mid-Stage Products (Phase II)
    Comparative Analysis
    Pre-Clinical Products
    Comparative Analysis
    Therapeutic Assessment: Active Products
    Assessment by Route of Administration
    Assessment by Stage and Route of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Dormant Products
    Comparative Analysis
    Appendix

    List of Figures, Tables and Charts Available in Eosinophilic Esophagitis- Pipeline Insight, 2018

    Table 1: Total Products for Eosinophilic Esophagitis
    Table 2: Late Stage Products (Phase III)
    Table 3: Mid Stage Products (Phase II)
    Table 4: Pre-clinical Products
    Table 5: Assessment by Route of Administration
    Table 6: Assessment by Stage and Route of Administration
    Table 7: Assessment by Molecule Type
    Table 8: Assessment by Stage and Molecule Type
    Table 9: Dormant Products


    Figure 1: Esophagus affected by Eosinophilic Esophagitis
    Figure 2: Endoscopy image showing rings, linear and narrow caliber
    Figure 3: Pathogenesis of Eosinophilic Esophagitis
    Figure 4: Total Products for Eosinophilic Esophagitis
    Figure 5: Late Stage Products (Phase III)
    Figure 6: Mid Stage Products (Phase II)
    Figure 7: Pre-clinical Products
    Figure 8: Assessment by Route of Administration
    Figure 9: Assessment by Stage and Route of Administration
    Figure 10: Assessment by Molecule Type
    Figure 11: Assessment by Stage and Molecule Type
    Figure 12: Dormant Products

    Keyplayers in Eosinophilic Esophagitis- Pipeline Insight, 2018

    Adare Pharmaceuticals
    Atopix Therapeutics
    Biotica Pharmaceuticals
    Calypso Biotech
    Celgene
    DBV Technologies
    GlaxoSmithKline
    Novartis
    Quorum Innovations
    Sanofi/Regeneron
    Shire
    Teva